These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25496749)

  • 1. Potential side effects to GLP-1 agonists: understanding their safety and tolerability.
    Consoli A; Formoso G
    Expert Opin Drug Saf; 2015 Feb; 14(2):207-18. PubMed ID: 25496749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
    Ottney A
    Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats.
    Sisley S; Smith K; Sandoval DA; Seeley RJ
    Peptides; 2014 Aug; 58():1-6. PubMed ID: 24879927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.
    Ryder RE
    Diabet Med; 2013 Oct; 30(10):1148-55. PubMed ID: 24073725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
    Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
    Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
    Jespersen MJ; Knop FK; Christensen M
    Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):17-29. PubMed ID: 23094590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
    Alves C; Batel-Marques F; Macedo AF
    Diabetes Res Clin Pract; 2012 Nov; 98(2):271-84. PubMed ID: 23010561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
    Lorber D
    Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
    Aroda VR; Ratner R
    Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.
    Chiu WY; Shih SR; Tseng CH
    Exp Diabetes Res; 2012; 2012():924168. PubMed ID: 22693487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.
    Su B; Sheng H; Zhang M; Bu L; Yang P; Li L; Li F; Sheng C; Han Y; Qu S; Wang J
    Endocrine; 2015 Feb; 48(1):107-15. PubMed ID: 25074632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.
    Monami M; Cremasco F; Lamanna C; Colombi C; Desideri CM; Iacomelli I; Marchionni N; Mannucci E
    Exp Diabetes Res; 2011; 2011():215764. PubMed ID: 21584276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.
    Montanya E
    Expert Opin Pharmacother; 2012 Jul; 13(10):1451-67. PubMed ID: 22725703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.